Clinical Course and Biomarkers Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Chinese Patients With Obesity

Recruiting Observational Study
Nonalcoholic Fatty Liver Disease (NAFLD)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
200 (estimated)
Sponsor
Chinese University of Hong Kong · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in many parts of the world. NAFLD can progress to nonalcoholic steatohepatitis (NASH) and result in cirrhosis and liver cancer. Despite NAFLD is common, there are a lot of knowledge gaps about this common disease including the progression from NAFLD to NASH and from fibrosis to cirrhosis, efficacious treatmen…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age 18 years or above * Chinese ethnicity * Patient undergoing obesity surgery at The Prince of Wales Hospital Exclusion Criteria: * Endocrine causes of obesity * Active uncontrolled psychiatric illness * Active substance abuse * Alcohol intake exceeding 30 grams per day in …
Contacts

Alice Pik Shan Kong, MD

+852 3505 2648

alicekong@cuhk.edu.hk

CONTACT